Search

Displaying results 1661 - 1670 of 10000 in total
  1. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    Marketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. … These biochemical changes result in a reduced tendency for self-association resulting in dissolution to a dimer and then to a monomer that is absorbed more rapidly after subcutaneous injection compared

    Mixtures: Humalog Mix 25 (pen), Humalog Mix 25 (pen)Categories: Drugs Used in Diabetes
  2. Drug

    Urapidil

    go.drugbank.com/drugs/DB12661
    Investigational

    Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

    Products: EBRANTIL 60 MG, UPADİL 50 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET
  3. Drug

    Metronidazole benzoate

    go.drugbank.com/drugs/DB15759
    Investigational

    Mixtures: DIARSET NX- M SUSPENSION, METRONIDAZOL BENZOILO/ NIFUROXAZIDA 250MG + 200MG/5 ML SUSPENSIONProducts: METRONIDAZOL 125 MG /5 ML., AMZOL®250 MG/5 ML SUSPENSIÓN
  4. Drug

    Leuvectin

    go.drugbank.com/drugs/DB17303
    Investigational

    Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE/DOPE).

    Synonyms: DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2Categories: Complex Mixtures
  5. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. … [A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe.

  6. Drug

    Lysozyme

    go.drugbank.com/drugs/DB13260
    Investigational

    Mixtures: LYSOBACT 20 MG/10 MG PASTİL, 30 ADET, E-zyme B6 TrocheProducts: NEUFLO TABLET 90 mg, LEFTOSE TABLETS (30 MG)
  7. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Patients on acenocoumarol are prohibited from giving blood. … Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.

    Products: Sintrom 4 mg Tabletten
  8. Drug

    Aprotinin

    go.drugbank.com/drugs/DB06692
    ApprovedInvestigationalWithdrawn

    The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. … Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death.

    Mixtures: ARTISS 10 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET, TISSEEL 10 ML ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR 1 ADETProducts: TRASYLOL INJECTION 500,000 kiu/50 ml, Trasylol 10 000 KIE/ml Infusionslösung
  9. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.

    Products: ALIZAPRIDA 50 MG/ 2 ML, ALIZAPRIDA SOLUCION INYECTABLE 50 MG/ 2 ML
  10. Target

    Transitional endoplasmic reticulum ATPase

    go.drugbank.com/bio_entities/BE0004572
    TargetHumans

    The NPLOC4-UFD1-VCP complex regulates spindle disassembly at the end of mitosis and is necessary for the formation of a closed nuclear envelope. … Mediates the endoplasmic reticulum-associated degradation of CHRNA3 in cortical neurons as part of the STUB1-VCP-UBXN2A complex (PubMed:26265139).

    Synonyms: 15S Mg(2+)-ATPase p97 subunit